ALK-Abello Overview
- Year Founded
-
1923
- Status
-
Public
- Employees
-
2,806
- Stock Symbol
-
ALK B
- Investments
-
11
- Share Price
-
$25.56
- (As of Friday Closing)
ALK-Abello General Information
Description
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Contact Information
Website
www.alk.netCorporate Office
- Boge Alle 6-8
- 2970 Horsholm
- Denmark
Corporate Office
- Boge Alle 6-8
- 2970 Horsholm
- Denmark
ALK-Abello Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.56 | $25.35 | $10.51 - $27.77 | $5.66B | 221M | 210K | $0.45 |
ALK-Abello Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 4,897,242 | 3,395,820 | 3,099,049 | 6,348,768 |
| Revenue | 751,375 | 700,048 | 637,567 | 622,665 |
| EBITDA | 169,567 | 125,237 | 93,988 | 76,641 |
| Net Income | 100,087 | 70,527 | 47,348 | 34,822 |
| Total Assets | 1,011,326 | 998,622 | 907,900 | 887,536 |
| Total Debt | 72,781 | 113,581 | 100,174 | 108,088 |
ALK-Abello Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ALK-Abello Executive Team (18)
| Name | Title | Board Seat |
|---|---|---|
| Peter Halling | Chief Executive Officer & President | |
| Claus Sølje | Executive Vice President & Chief Financial Officer | |
| Helle Sandal | Coordinator, Investor Relations | |
| Søren Niegel | Executive Vice President, Commercial Operations | |
| Rasmus Just | Head, Business Development |
ALK-Abello Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 0000 | Self | Board Member | 000 0000 |
| 000000 00000000 00 | Self | Board Member | 000 0000 |
| 00000 0000000 | Self | Board Member | 000 0000 |
| 0000 00000 | Self | Board Member & Vice Chairman | 000 0000 |
| 0000 0000000000 | Self | Board Member | 000 0000 |
ALK-Abello Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ALK-Abello Investments & Acquisitions (11)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Allerquest | 02-Jan-2024 | 0000000000 | 000.00 | Pharmaceuticals | 0000 0000 |
| Otonomy (Otiprio Fluoroquinolone Antibacterial) | 28-May-2021 | 000000000 | Pharmaceuticals | 00000 000 | |
| Betamab Therapeutics | 20-Apr-2020 | 000000000 | Drug Delivery | ||
| Allergy Laboratories | 03-Jan-2017 | 0000000000 | Pharmaceuticals | 00000000 | |
| Crystal Laboratory | 03-Jan-2017 | Merger/Acquisition | Drug Discovery | 00000000 |
ALK-Abello Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Allerquest | Pharmaceuticals | Monroe, CT | 2005 |
| Nelco Vet | Other Pharmaceuticals and Biotechnology | New York, NY | 0000 |
| Western Allergy Services | Pharmaceuticals | Victoria, Canada | 0000 |
ALK-Abello ESG
Risk Overview
Risk Rating
Updated May, 19, 2024
19.27 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
ALK-Abello Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Actt | 12-Feb-2014 | 000000000000 | 00.000 | Completed |
|
| DBV Technologies | 05-Jan-2011 | 00000 00000 | 000.00 | Completed |
|
| DBV Technologies | 21-Jan-2009 | Later Stage VC | 00.000 | Completed |
|
ALK-Abello FAQs
-
When was ALK-Abello founded?
ALK-Abello was founded in 1923.
-
Who is the CEO of ALK-Abello?
Peter Halling is the CEO of ALK-Abello.
-
Where is ALK-Abello headquartered?
ALK-Abello is headquartered in Horsholm, Denmark.
-
What is the size of ALK-Abello?
ALK-Abello has 2,806 total employees.
-
What industry is ALK-Abello in?
ALK-Abello’s primary industry is Drug Discovery.
-
Is ALK-Abello a private or public company?
ALK-Abello is a Public company.
-
What is ALK-Abello’s stock symbol?
The ticker symbol for ALK-Abello is ALK B.
-
What is the current stock price of ALK-Abello?
As of 06-Sep-2024 the stock price of ALK-Abello is $25.56.
-
What is the current market cap of ALK-Abello?
The current market capitalization of ALK-Abello is $5.66B.
-
What is ALK-Abello’s current revenue?
The trailing twelve month revenue for ALK-Abello is $751M.
-
What is ALK-Abello’s annual earnings per share (EPS)?
ALK-Abello’s EPS for 12 months was $0.45.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
